Syncom Formulations Reports Strong Q2 FY27 Results Driven by Pharmaceuticals Growth
Syncom Formulations India Ltd · Financial Result · 13 Nov 2026, 10:29 pm
Syncom Formulations Reports Strong Q2 FY27 Results Driven by Pharmaceuticals Growth Syncom Formulations reported a consolidated revenue from operations of ₹14,214.49 lakhs for Q2 ended 30th Sep'26, rising 16.78% YoY and 13.24% QoQ. Consolidated net profit reached ₹2,665.32 lakhs, marking a 60.55% YoY and 7.27% QoQ growth. PBT climbed 63.49% YoY to ₹3,602.77 lakhs, primarily propelled by the core pharmaceuticals segment delivering ₹3,517.63 lakhs in profit. Restated basic and diluted EPS improved to ₹0.28 from ₹0.18 YoY. For H1 ended 30th Sep'26, consolidated revenue stood at ₹26,767.13 lakhs with net profit of ₹5,150.00 lakhs.
Original exchange filing (PDF)
More announcements from Syncom Formulations India Ltd
- Syncom Formulations (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 13 Nov 2026
- Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit herewith the following: 1. Standalone and Consolidated Un-Audited Financial Results of the Company .... · 13 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters · 13 Nov 2026
- SYNCOM FORMULATIONS (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 13 Nov 2026
- Syncom Formulations India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Pursuant to Regulation .... · 13 Nov 2026
- Corporate Announcement regarding approval and payment of final dividend. · 02 Oct 2026
- Disclosure under reg 30 of SEBI (LODR) reg 2015 read with sub clause 7 of para A of part A of schedule /// change in directorate. · 02 Oct 2026
- Outcome of 38th AGM · 02 Oct 2026
